|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:adjuvant
|
no
|
|
gptkbp:administeredBy
|
over 170 countries
intramuscular injection
|
|
gptkbp:age
|
18 and older
|
|
gptkbp:alsoKnownAs
|
gptkb:ChAdOx1_nCoV-19
gptkb:AZD1222
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:India
gptkb:United_Kingdom
2020
many other countries
|
|
gptkbp:boosterDosePossible
|
yes
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:contains
|
SARS-CoV-2 spike protein gene
replication-deficient chimpanzee adenovirus vector
|
|
gptkbp:containsDNA
|
yes
|
|
gptkbp:containsLiveVirus
|
no
|
|
gptkbp:containsmRNA
|
no
|
|
gptkbp:containsPreservative
|
no
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:distribution
|
global
|
|
gptkbp:dosesRequired
|
2
|
|
gptkbp:efficacyAgainstDeath
|
high
|
|
gptkbp:efficacyAgainstHospitalization
|
high
|
|
gptkbp:efficacyAgainstSevereDisease
|
high
|
|
gptkbp:emergencyServices
|
gptkb:World_Health_Organization
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vaxzevria
|
|
gptkbp:includedInCOVAX
|
yes
|
|
gptkbp:includedInEU
|
yes
|
|
gptkbp:includedInIndia
|
yes
|
|
gptkbp:includedInUK
|
yes
|
|
gptkbp:includedInWHO
|
yes
|
|
gptkbp:manufacturer
|
gptkb:Serum_Institute_of_India
|
|
gptkbp:marketedAs
|
Covishield (in India)
|
|
gptkbp:notRecommendedFor
|
people with history of severe allergic reaction to any ingredient
|
|
gptkbp:pregnancyCategory
|
consult healthcare provider
|
|
gptkbp:refrigerationRequired
|
yes
|
|
gptkbp:regulatorySuspension
|
some countries temporarily suspended due to clotting concerns
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
rare blood clotting events
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:type
|
viral vector vaccine
|
|
gptkbp:WHOListStatus
|
gptkb:EUL_(Emergency_Use_Listing)
|
|
gptkbp:bfsParent
|
gptkb:AstraZeneca_COVID-19_vaccine
gptkb:Covishield
gptkb:阿斯利康
|
|
gptkbp:bfsLayer
|
5
|